OMB Control Number:
Expiration Date:

DEFENSE INDUSTRIAL BASE ASSESSMENT:
Healthcare and Public Health (HPH) Sector
Survey for Manufacturers

SCOPE OF ASSESSMENT

The U.S. Department of Commerce, Bureau of Industry and Security (BIS), Office of Technology Evaluation (OTE), in coordination with the Department of Homeland Security (DHS), is conducting an assessment regarding the supply chain within the Healthcare and Public Health (HPH) sector. The principal goal of this assessment is to identify foreign sourcing, critical dependencies and other supply chain issues that could have a negative impact on the delivery of effective medical services in the United States.

RESPONSE TO THIS SURVEY IS REQUIRED BY LAW

A response to this survey is required by law (50 U.S.C. app. Sec. 2155). Failure to respond can result in a maximum fine of $10,000, imprisonment of up to one year, or both. Information furnished herewith is deemed confidential and will not be published or disclosed except in accordance with Section 705 of the Defense Production Act of 1950, as amended (50 U.S.C App. Sec. 2155). Section 705 prohibits the publication or disclosure of this information unless the President determines that its withholding is contrary to the national defense. Information will not be shared with any non-government entity, other than in aggregate form. The information will be protected pursuant to the appropriate exemptions from disclosure under the Freedom of Information Act (FOIA), should it be the subject of a FOIA request.

Not withstanding any other provision of law, no person is required to respond to nor shall a person be subject to a penalty for failure to comply with a collection of information subject to the requirements of the Paperwork Reduction Act unless that collection of information displays a currently valid OMB Control Number.

BURDEN ESTIMATE AND REQUEST FOR COMMENT

Public reporting burden for this collection of information is estimated to average 13 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information to BIS Information Collection Officer, Room 6883, Bureau of Industry and Security, U.S. Department of Commerce, Washington, D.C. 20230, and to the Office of Management and Budget, Paperwork Reduction Project **(OMB Control No.)**, Washington, D.C. 20503.

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section I	General Instructions
A.	Your company is required to complete this survey using an Excel template, which can be downloaded from the BIS website. At your request, BIS staff will e-mail the Excel survey template directly to your company. For your convenience, a PDF version of the survey is available on the BIS website to aid internal data collection. PLEASE DO NOT submit the PDF version of your company's response to BIS.
B.	If information is not available from your records in the form requested, you may furnish estimates. Please indicate in the comment box on the page when you use an estimate.
C.	Questions related to this survey should be directed to: Anna Bruse, Trade and Industry Analyst, (202) 482-7418 Erika Maynard, Trade and Industry Analyst, (202) 482-5572 Michael Finucane, Trade and Industry Analyst, (202) 482-3893
D.	Upon completion, review and certification of the survey, transmit the survey via e-mail to CFDHealthcare@bis.doc.gov.
E.	For letter correspondence to the Office of Technology Evaluation (OTE), please write to: Brad Botwin, Director, Industrial Studies Office of Technology Evaluation, Room 1093 U.S. Department of Commerce 1401 Constitution Avenue, NW Washington, DC 20230 Please do not submit completed surveys to this address; all surveys must be submitted electronically.

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section II	Who Must Respond			
A.	Has your company manufactured or integrated/assembled healthcare-related pharmaceutical, equipment, or device products between 2007-2010?			
B.	Identify the **general product areas** your company manufacturers or integrates/assembles from the list below, as applicable.			
	Anaesthetics		Cancer Treatments	
	Analgesics		Cardiovasculars	
	Antibacterials		Hormones	
	Antibiotics		Immunosupressants	
	Anticonvulsants, Sedatives, Relaxants		Stimulants	
	Anti-Inflammatories		Vaccines	
	Antileprosy		Surgical and Medical Instruments	
	Antiprotozoals		Medical Devices	
	Antivirals			
C.	Does your company also manufacture or integrate/assemble non-healthcare related pharmaceutical, equipment, or device products?			
	If 'Yes,' indicate the percentage of your business that is not related to healthcare pharmaceutical, equipment, or device products:			

Exemption From Survey

If you answered "No" to Question B above, you may be exempt from completing this U.S. Government survey. Please review the products identified in the Critical Commodities List (Sections 2.a through 2.h on this survey). If your company **does not** manufacture any of these products, **complete Section 1.c** and call one of the BIS contacts listed on the previous page.

Comments:	

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section III	Definitions
Alternate Source	A supplier of the same product or an alternative product that, in the opinion of experts qualified by scientific training and experience to evaluate the safety and effectiveness of pharmaceuticals and/or medical devices, it is prudent to assume or ascertain the liability of similar side effects and contraindications.
Component	Any raw material, substance, piece, part, software, firmware, labeling, or assembly which is intended to be included as part of the finished, packaged, and labeled device.
Disruption Clauses	Contract provisions that impose penalties on suppliers to recoup losses in the advent of a delivery/service delay or interruption.
Finished Product	Any device, accessory to any device, or drug product, that is suitable for use or capable of functioning, whether or not it is packaged, labeled, or sterilized.
Manufacturing Material	Any material or substance used in or used to facilitate the manufacturing process, a concomitant constituent, or a byproduct constituent produced during the manufacturing process, which is present in or on the finished device/product as a residue or impurity not by design or intent of the manufacturer.
Sole Source/Sole Manufacturer	A supplier that is the only manufacturer or distributor of a product. For this product, there are either 1) no alternate products or 2) potential alternate products have substantially different levels of effectiveness and/or potential side effects.
Surge Capacity Provisions	Contract provisions that allow the contracting party to a) increase the quantity of products or services called for under the contract by a certain amount; and/or b) accelerate the rate of delivery established under the contract.

Section 1.a		Company Information			
A.	Company Name				
	Street Address				
	City				
	State				
	Zip Code				
	Phone Number				
	Fax Number				
	Website				
B.	Point of Contact(s) regarding this survey:				
	Name	Title	E-mail	Phone Number	
	Comments:				

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 1.b **Company Ownership Information**

A.	My company is headquartered in:					
	My company is:					
	Parent Company Name	Address		City	State/Province	Country
	My company is Public/Private:					
	My parent company is Public/Private:					

B. Please identify the entities and/or individuals currently holding 5 percent or more of your company's or organization's voting rights. List no more than 5, if applicable, and place them in descending order, the highest percentage stake listed first. This question applies to both public and privately held companies.

	Entity or Individual's Name	Stake (%)	Address	City	State/Province	Country
1.						
2.						
3.						
4.						
5.						

C. From 2007-2010, has one or more foreign governments invested, directly or indirectly, in your company and control 5 percent or more of stockholder voting shares?

If you answered "Yes," please explain the type of investment and identify the foreign government(s).

	Type of Investment	Foreign Government
1.		
2.		
3.		
4.		
5.		

Comments:	

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 1.c	Manufacturing Facilities					
A.	Identify the facilities your company owns and operates **in the United States** for the manufacture or integration/assembly of healthcare-related pharmaceutical, equipment, or device products. Provide the name and location for each facility.					
	ID #	Facility Name	Street Address	City	State	Zip Code
	US - 1					
	US - 2					
	US - 3					
	US - 4					
	US - 5					
	US - 6					
	US - 7					
	US - 8					
	US - 9					
	US - 10					
	US - 11					
	US - 12					
	US - 13					
	US - 14					
	US - 15					
B.	Identify the facilities your company owns and operates **outside the United States** for the manufacture or integration/assembly of healthcare-related pharmaceutical, equipment, or device products. Provide the name and location for each facility.					
	ID #	Facility Name	Street Address	City	State/Province	Country
	Non-US - 1					
	Non-US - 2					
	Non-US - 3					
	Non-US - 4					
	Non-US - 5					
	Non-US - 6					
	Non-US - 7					
	Non-US - 8					
	Non-US - 9					
	Non-US - 10					
	Non-US - 11					
	Non-US - 12					
	Non-US - 13					
	Non-US - 14					
	Non-US - 15					
	Comments:					

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 2.a **Critical Commodities List**

From the product areas listed below, indicate those that your company currently manufactures or integrates/assembles. For each area, identify the top three discrete products (by an estimate of annual sales) your company currently produces and whether your company, to the best of your knowledge, is the sole U.S.-based manufacturer, sole global manufacturer, or not a sole manufacturer of this product. If you are not sure, select "Not Sure" from the drop-down box. Finally, indicate the primary manufacturing facility in which each product is produced (the facility that adds the most value to the finished product) based on those identified in Section 1.c.

Differentiate products based on their unique effects or capabilities. Do not differentiate products based solely on dosage, strength, or method of delivery.

Note: If the product you manufacture does not fit the product area exactly (e.g. it is a combination of multiple product areas, your company classifies its product under a similar, but different area, etc.) make note of this in the comments area in the far right column.

Note: For the purposes of this survey a sole manufacturer is the only manufacturer of a product of a particular use, capability, or function. For this product, there are either 1) no alternate products or 2) potential alternate products have substantially different levels of effectiveness and/or potential side effects.

Anaesthetics

Product Area	Manufacture?	1			2			3			Product Area Comments
		Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
A1 Atropine/Atropine Sulfate											
A2 Bupivacaine											
A3 Halothane											
A4 Ketamine											
A5 Lidocaine											
A6 Nitrous Oxide											
A7 Pancuronium Bromide											
A8 Promethazine											
A9 Propofol											
A10 Thiopental/Pentothal											
A11 Thiopentone Sodium											

Analgesics

Product Area	Manufacture?	1			2			3			Product Area Comments
		Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
B1 Acetylsalicyclic Acid (Aspirin)											
B2 Allopurinol											
B3 Aminophenazone											
B4 Azathioprine											
B5 Buprenorphine											
B6 Carbamazepine											
B7 Chloroquine											
B8 Cinchonine											
B9 Codeine											
B10 Dihydrocodeine											
B11 Etorphine											
B12 Hydrocodone											
B13 Hydromorphone											
B14 Ibuprofen											
B15 Levorphanol											
B16 Methotrexate											
B17 Morphine											
B18 Nicomorphine											
B19 Oxycodone											
B20 Oxymorphone											
B21 Paracetamol/Acetaminophen											
B22 Penicillamine											
B23 Pholcodine											
B24 Quinine											
B25 Thebacon											

Antibacterials

Product Area	Manufacture?	1			2			3			Product Area Comments
		Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
C1 Furazolidone											
C2 Sulferamerazine											

C3	Sulphadiazine											
C4	Sulphapyridine											
C5	Sulphathiazole											
C6	Sulphathiourea											
Comments:												

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 2.b **Critical Commodities List**

From the product areas listed below, indicate those that your company currently manufactures or integrates/assembles. For each area, identify the top three discrete products (by an estimate of annual sales) your company currently produces and whether your company, to the best of your knowledge, is the sole U.S.-based manufacturer, sole global manufacturer, or not a sole manufacturer of this product. If you are not sure, select "Not Sure" from the drop-down box. Finally, indicate the primary manufacturing facility in which each product is produced (the facility that adds the most value to the finished product) based on those identified in Section 1.c.

Differentiate products based on their unique effects or capabilities. Do not differentiate products based solely on dosage, strength, or method of delivery.

Note: If the product you manufacture does not fit the product area exactly (e.g. it is a combination of multiple product areas, your company classifies its product under a similar, but different area, etc.) make note of this in the comments area in the far right column.

Note: For the purposes of this survey a sole manufacturer is the only manufacturer of a product of a particular use, capability, or function. For this product, there are either 1) no alternate products or 2) potential alternate products have substantially different levels of effectiveness and/or potential side effects.

Antibiotics

Product Area		Manufacture?	1			2			3			Product Area Comments
			Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
D1	Actinomycins											
D2	Amoxicillin											
D3	Ampicillin											
D4	Azithromycin											
D5	Aztreonam											
D6	Bacitracin											
D7	Benzylpenicillin (Penicillin G)											
D8	Cefalexin											
D9	Cefazolin											
D10	Cefixime											
D11	Cefotaxime											
D12	Ceftazidime											
D13	Ceftriaxone											
D14	Chloramphenicol											
D15	Ciprofloxacin											
D16	Clarithromycin											
D17	Clindamycin											
D18	Cloxacillin											
D19	Doripenem											
D20	Doxycycline											
D21	Erythromycin											
D22	Gentamicin											
D23	Gramicidines											
D24	Imipenem											
D25	Levofloxacin											
D26	Metronidazole											
D27	Minocycline											
D28	Nitrofurantoin											
D29	Phenoxymethylpenicillin											
D30	Procaine Benzylpenicillin											
D31	Sarkomycin											
D32	Spectinomycin											
D33	Streptomycin											
D34	Talampicillin											
D35	Tetracycline											
D36	Thiamphenicol											
D37	Trimethoprim											
D38	Tyrocidin											
D39	Vancomycin											
D40	Zanamivir											
Comments:												

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 2.c **Critical Commodities List**

From the product areas listed below, indicate those that your company currently manufactures or integrates/assembles. For each area, identify the top three discrete products (by an estimate of annual sales) your company currently produces and whether your company, to the best of your knowledge, is the sole U.S.-based manufacturer, sole global manufacturer, or not a sole manufacturer of this product. If you are not sure, select "Not Sure" from the drop-down box. Finally, indicate the primary manufacturing facility in which each product is produced (the facility that adds the most value to the finished product) based on those identified in Section 1.c.

Differentiate products based on their unique effects or capabilities. Do not differentiate products based solely on dosage, strength, or method of delivery.

Note: If the product you manufacture does not fit the product area exactly (e.g. it is a combination of multiple product areas, your company classifies its product under a similar, but different area, etc.) make note of this in the comments area in the far right column.

Note: For the purposes of this survey a sole manufacturer is the only manufacturer of a product of a particular use, capability, or function. For this product, there are either 1) no alternate products or 2) potential alternate products have substantially different levels of effectiveness and/or potential side effects.

Anticonvulsants, Sedatives, Relaxants

Product Area		Manufacture?	1			2			3			Product Area Comments
			Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
E1	Alprazolam											
E2	Atracurium Besylate											
E3	Camazepam											
E4	Chlordiazepoxide											
E5	Clonazepam											
E6	Clorazepate											
E7	Delorazepam											
E8	Diazepam											
E9	Estazolam											
E10	Ethosuximide											
E11	Ethyl Loflazepate											
E12	Fludiazepam											
E13	Flunitrazepam											
E14	Flurazepam											
E15	Halazepam											
E16	Lorazepam											
E17	Lormetazepam											
E18	Mazindol											
E19	Medazepam											
E20	Midazolam											
E21	Nimetazepam											
E22	Nitrazepam											
E23	Nordazepam											
E24	Oxazepam											
E25	Phenobarbital											
E26	Phenytoin											
E27	Pinazepam											
E28	Pralidoxime/Pralidoxime Chloride											
E29	Prazepam											
E30	Pyrovalerone											
E31	Temazepam											
E32	Tetrazepam											
E33	Triazolam											
E34	Valproic Acid (VPA)											
E35	Vecuronium Bromide											

Anti-Inflammatories

Product Area		Manufacture?	1			2			3			Product Area Comments
			Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
F1	Dexamthasone											
F2	Flucinolone Acetonide											
F3	Indometacin/Indomethacin											
F4	Rutoside/Rutin											
F5	Tolmetin											
Comments:												

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 2.d **Critical Commodities List**

From the product areas listed below, indicate those that your company currently manufactures or integrates/assembles. For each area, identify the top three discrete products (by an estimate of annual sales) your company currently produces and whether your company, to the best of your knowledge, is the sole U.S.-based manufacturer, sole global manufacturer, or not a sole manufacturer of this product. If you are not sure, select "Not Sure" from the drop-down box. Finally, indicate the primary manufacturing facility in which each product is produced (the facility that adds the most value to the finished product) based on those identified in Section 1.c.

Differentiate products based on their unique effects or capabilities. Do not differentiate products based solely on dosage, strength, or method of delivery.

Note: If the product you manufacture does not fit the product area exactly (e.g. it is a combination of multiple product areas, your company classifies its product under a similar, but different area, etc.) make note of this in the comments area in the far right column.

Note: For the purposes of this survey a sole manufacturer is the only manufacturer of a product of a particular use, capability, or function. For this product, there are either 1) no alternate products or 2) potential alternate products have substantially different levels of effectiveness and/or potential side effects.

Antileprosy

Product Area	Manufacture?	1			2			3			Product Area Comments
		Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
G1 Amikacin											
G2 Capreomycin											
G3 Clofazimine											
G4 Cycloserine											
G5 Dapsone											
G6 Ethambutol											
G7 Ethionamide											
G8 Isoniazid											
G9 Kanamycin											
G10 Ofloxacin											
G11 P-Aminosalicylic Acid											
G12 Pyrazinamide											
G13 Rifabutin											
G14 Rifampicin/Rifampin											

Antiprotozoals

Product Area	Manufacture?	1			2			3			Product Area Comments
		Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
H1 Amodiaquine											
H2 Artemether											
H3 Benznidazole											
H4 Diloxanide											
H5 Eflornithine											
H6 Mefloquine											
H7 Nicarbazin											
H8 Nifurtimox											
H9 Paramomycin											
H10 Pentamidine											
H11 Primaquine											
H12 Proguanil											
H13 Pyrimethamine											

Antivirals

Product Area	Manufacture?	1			2			3			Product Area Comments
		Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
I1 Abacavir (ABC)											
I2 Acyclovir											
I3 Amantadine											
I4 Atazanavir											
I5 Cidofovir											
I6 Didanosine (ddl)											
I7 Efavirenz (EFV or EFZ)											
I8 Indinavir (DIV)											
I9 Lamivudine (3TC)											
I10 Nevirapine (NVP)											
I11 Oseltamivir (aka Tamiflu)											
I12 Ribavirin											

I13	Rimantadine											
I14	Ritonavir											
I15	Saquinavir (SQV)											
I16	Stavudine (d4T)											
I17	Tenofovir Disoproxil Fumarate (TDF)											
I18	Zidovudine (ZDV or AZT)											
Comments:												

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 2.e **Critical Commodities List**

From the product areas listed below, indicate those that your company currently manufactures or integrates/assembles. For each area, identify the top three discrete products (by an estimate of annual sales) your company currently produces and whether your company, to the best of your knowledge, is the sole U.S.-based manufacturer, sole global manufacturer, or not a sole manufacturer of this product. If you are not sure, select "Not Sure" from the drop-down box. Finally, indicate the primary manufacturing facility in which each product is produced (the facility that adds the most value to the finished product) based on those identified in Section 1.c.

Differentiate products based on their unique effects or capabilities. Do not differentiate products based solely on dosage, strength, or method of delivery.

Note: If the product you manufacture does not fit the product area exactly (e.g. it is a combination of multiple product areas, your company classifies its product under a similar, but different area, etc.) make note of this in the comments area in the far right column.

Note: For the purposes of this survey a sole manufacturer is the only manufacturer of a product of a particular use, capability, or function. For this product, there are either 1) no alternate products or 2) potential alternate products have substantially different levels of effectiveness and/or potential side effects.

Cancer Treatments

Product Area		Manufacture?	1			2			3			Product Area Comments
			Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
J1	Folinic Acid/Leucovorin											
J2	Thiotepa											
J3	Valrubicin											
J4	Vinblastine Sulfate											

Cardiovasculars

Product Area		Manufacture?	1			2			3			Product Area Comments
			Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
K1	Amiodarone											
K2	Amlodipine											
K3	Arnolol											
K4	Atenolol											
K5	Digoxin											
K6	Dopamine											
K7	Enalapril											
K8	Furosemide											
K9	Glyceryl Trinitrate											
K10	Hydralazine Hydrochloride											
K11	Hydrochlorothiazide											
K12	Isosorbide Dinitrate											
K13	Mexiletine											
K14	Sarpogrelate											
K15	Simvastatin											
K16	Streptokinase											
K17	Verapamil											

Hormones

Product Area		Manufacture?	1			2			3			Product Area Comments
			Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
L1	Aglepristone											
L2	Estradiol											
L3	Estriol											
L4	Estrone											
L5	Ethinyl Estradiol											
L6	Fludrocortisone											
L7	Glibenclamide											
L8	Granulocyte-Colony Stimulating Factor (G-CSF)											
L9	Insulin											
L10	Levonorgestrel											
L11	Levothyroxine											
L12	Liothyronine											
L13	Medroxyprogesterone Acetate											
L14	Mestranol											
L15	Metformin											
L16	Norethisterone											
L17	Onapristone											

L18	Pegvisomant											
L19	Potassium Iodide											
L20	Pregnandiol											
L21	Progesterone											
L22	Propylthiouracil											
L23	Rathyronine											
L24	Somatotropin											
L25	Somatrem											
L26	Somenopor											
L27	Testosterone (Androgen)											
Comments:												

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 2.f **Critical Commodities List**

From the product areas listed below, indicate those that your company currently manufactures or integrates/assembles. For each area, identify the top three discrete products (by an estimate of annual sales) your company currently produces and whether your company, to the best of your knowledge, is the sole U.S.-based manufacturer, sole global manufacturer, or not a sole manufacturer of this product. If you are not sure, select "Not Sure" from the drop-down box. Finally, indicate the primary manufacturing facility in which each product is produced (the facility that adds the most value to the finished product) based on those identified in Section 1.c.

Differentiate products based on their unique effects or capabilities. Do not differentiate products based solely on dosage, strength, or method of delivery.

Note: If the product you manufacture does not fit the product area exactly (e.g. it is a combination of multiple product areas, your company classifies its product under a similar, but different area, etc.) make note of this in the comments area in the far right column.

Note: For the purposes of this survey a sole manufacturer is the only manufacturer of a product of a particular use, capability, or function. For this product, there are either 1) no alternate products or 2) potential alternate products have substantially different levels of effectiveness and/or potential side effects.

Immunosuppressants

Product Area		Manufacture?	1			2			3			Product Area Comments
			Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
M1	Aldosterone											
M2	Asparaginase											
M3	Bleomycin											
M4	Calcium Folinate											
M5	Carboplatin											
M6	Chlorambucil											
M7	Ciclosporin											
M8	Cortisone											
M9	Cortodoxone											
M10	Cyclophosphamide											
M11	Cytarabine											
M12	Dactinomycin											
M13	Darcabazine											
M14	Daunorubicin											
M15	Etoposide											
M16	Fluorouracil											
M17	Hydrocortisone											
M18	Hydrooxycarbamide											
M19	Ifosfamide											
M20	Mercaptopurine											
M21	Mesna											
M22	Prednisolone											
M23	Prednisone											
M24	Procarbazine											
M25	Tamoxifen											
M26	Vinblastine											
M27	Vincristine											

Stimulants

Product Area		Manufacture?	1			2			3			Product Area Comments
			Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
N1	Aminorex											
N2	Brotizolam											
N3	Clotiazepam											
N4	Ephedrine											
N5	Epinephrine (Adrenaline)											
N6	Fenethylline											
N7	Norepinephrine											
N8	Pseudoephedrine											
N9	Racepinephrine											

Vaccines

Product Area		Manufacture?	1			2			3			Product Area Comments
			Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
O1	Anthrax Treatments (Immune Globulin Injection, Raxibacumab, etc.)											

O2	BCG Vaccine											
O3	Cholera Vaccine											
O4	Diphtheria Vaccine											
O5	Haemophilus Influenzae Type B Vaccine											
O6	Hepatitis A Vaccine											
O7	Hepatitis B Vaccine											
O8	Japanese Encephalitis Vaccine											
O9	Measles Vaccine											
O10	Meningococcal Meningitis Vaccine											
O11	Modified Vaccinia Ankara (MVA)											
O12	Mumps Vaccine											
O13	Pertussis Vaccine											
O14	Pneumococcal Vaccine											
O15	Poliomyelitis Vaccine											
O16	Rabies Vaccine											
O17	Rotavirus Vaccine											
O18	Rubella Vaccine											
O19	Smallpox Vaccine											
O20	Tetanus Vaccine											
O21	Typhoid Vaccine											
O22	Vaccinia Immune Globulin (VIG)											
O23	Varicella Vaccine											
O24	Yellow Fever Vaccine											

Other Products

Product Area		Manufacture?	1			2			3			Product Area Comments
			Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
P1	Acridine											
P2	Botulinum Toxin(s)											
P3	Cyanide Treatments - Amyl Nitrate											
P4	Cyanide Treatments - Hydroxocabalamin											
P5	Cyanide Treatments - Sodium Nitrate											
P6	Cyanide Treatments - Sodium Thiosulfate											
P7	Diethylene Triamine Pentaacetic Acid (DTPA)/Pentetic Acid											
P8	Granisetron											
P9	Heparin											
P10	Imipramine											
P11	Lysine											
P12	Probenecid											
P13	Prussian Blue											
P14	Technetium Generators or other equipment for the processing of radioisotopes											
P15	Thiopen											

Comments:	

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 2.g **Critical Commodities List**

From the product areas listed below, indicate those that your company currently manufactures or integrates/assembles. For each area, identify the top three discrete products (by an estimate of annual sales) your company currently produces and whether your company, to the best of your knowledge, is the sole U.S.-based manufacturer, sole global manufacturer, or not a sole manufacturer of this product. If you are not sure, select "Not Sure" from the drop-down box. Finally, indicate the primary manufacturing facility in which each product is produced (the facility that adds the most value to the finished product) based on those identified in Section 1.c.

Differentiate products based on their unique effects or capabilities. Do not differentiate products based solely on dosage, strength, or method of delivery.

Note: If the product you manufacture does not fit the product area exactly (e.g. it is a combination of multiple product areas, your company classifies its product under a similar, but different area, etc.) make note of this in the comments area in the far right column.

Note: For the purposes of this survey a sole manufacturer is the only manufacturer of a product of a particular use, capability, or function. For this product, there are either 1) no alternate products or 2) potential alternate products have substantially different levels of effectiveness and/or potential side effects.

Surgical and Medical Instruments

	Product Area	Manufacture?	1			2			3			Product Area Comments
			Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
Q1	Adhesive Dressings											
Q2	Aerosol Therapy Apparatus											
Q3	Anaesthesia Units											
Q4	Anaesthetic Apparatus											
Q5	Anti-Radiation Protective Suits											
Q6	Apnea Monitors											
Q7	Apparatus Based on Alpha, Beta, or Gamma Radiations for Medical Use											
Q8	Argon Enhanced Coagulation Units											
Q9	Artificial Kidney/Dialysis Apparatus											
Q10	Artificial Respiration Apparatus											
Q11	Aspirators											
Q12	Auriscopes											
Q13	Blood Collection Tubes											
Q14	Blood Pressure Measuring Equipment											
Q15	Blood Transfusion Apparatus											
Q16	Bone Nails and Screws											
Q17	Bone Plates											
Q18	Bronchoscopes											
Q19	Capnographs											
Q20	Cardioscopes											
Q21	IV Catheters											
Q22	Adult Central Venous Catheters											
Q23	Pediatric Central Venous Catheters											
Q24	Swan-Ganz Catheters											
Q25	Suction Catheters											
Q26	Other Catheters											
Q27	Cauteries											
Q28	Cephalometers											
Q29	Crutches											
Q30	Cutaneous Dressings											
Q31	Defibrillators											
Q32	Dilators											
Q33	Electrocardiographs											
Q34	Electroencephalographs (EEG)											
Q35	Electronic Nerve Stimulation Machines											
Q36	Electrosphygmographs											
Q37	Electrotonographs											
Q38	Endoscopes											
Q39	Endotracheal Tubes (adult and pediatric)											

Q40	Fetal Monitors											
Q41	Forceps											
Q42	Gas Masks											
Q43	Gastroscopes											
Q44	Gauze and Bandages											
Q45	Gouges											
Q46	Hyperbaric Chambers											
Q47	Hysterectomy Instruments											
Q48	Infant Incubators											
Q49	Influenza Tests											
Q50	Infusion/IV Pumps											
Q51	Intubation Tubes											
Q52	Keratometer											
Q53	Kidney Dishes											
Q54	Lancets											
Q55	Laparoscopic Insufflators											
Q56	Laryngoscope											
Q57	Laryngoscope Handle and Blade (Intubating)											
Q58	Lensometer											
Q59	Liquid Dressings											
Q60	Lithotrity Instruments											
Q61	Lytic Bacteriophages											
Q62	Magnetic Resonance Imaging (MRI) Apparatus											
Q63	Mallets and Hammers for Medical Use											
Q64	Medical Needles/Syringes/Safety Needle											
Q65	Mirrors and Reflectors for Medical Use											
Q66	Nasal Cannula											
Q67	Nasogastric Tube (adult and pediatric)											
Q68	Nebulisers											
Q69	Oesophagoscopes											
	Comments:											

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 2.h **Critical Commodities List**

From the product areas listed below, indicate those that your company currently manufactures or integrates/assembles. For each area, identify the top three discrete products (by an estimate of annual sales) your company currently produces and whether your company, to the best of your knowledge, is the sole U.S.-based manufacturer, sole global manufacturer, or not a sole manufacturer of this product. If you are not sure, select "Not Sure" from the drop-down box. Finally, indicate the primary manufacturing facility in which each product is produced (the facility that adds the most value to the finished product) based on those identified in Section 1.c.

Differentiate products based on their unique effects or capabilities. Do not differentiate products based solely on dosage, strength, or method of delivery.

Note: If the product you manufacture does not fit the product area exactly (e.g. it is a combination of multiple product areas, your company classifies its product under a similar, but different area, etc.) make note of this in the comments area in the far right column.

Note: For the purposes of this survey a sole manufacturer is the only manufacturer of a product of a particular use, capability, or function. For this product, there are either 1) no alternate products or 2) potential alternate products have substantially different levels of effectiveness and/or potential side effects.

Surgical and Medical Instruments (cont.)

Product Area		Manufacture?	1			2			3			Product Area Comments
			Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	Product Name	Sole Manufacturer?	Manufacturing Facility	
Q70	Oropharyngeal Airway											
Q71	Oscillometers											
Q72	Oxygen Analyzers											
Q73	Oxygen Tents											
Q74	Oxygen Therapy Apparatus											
Q75	Ozone Therapy Apparatus											
Q76	Pacemakers											
Q77	Parts for Pacemakers											
Q78	Pelvimeters											
Q79	Phonocardiographs											
Q80	Protective Sceens/Shields for X-Ray Facilities											
Q81	Pulse Oxymiters											
Q82	Pyrometers											
Q83	Radiotherapy Apparatus											
Q84	Respirators											
Q85	Respiratory Pumps and Filters											
Q86	Resuscitator Bag Valves and Masks											
Q87	Pulmonary Resuscitators											
Q88	Oxygen Resuscitators											
Q89	Retractors											
Q90	Rheocardiographs											
Q91	Saws and Scrapers for Medical Use											
Q92	Sissors and Shears for Medical Use											
Q93	Spatulae											
Q94	Specula											
Q95	Sphygmomanometers											
Q96	Spinal Needles											
Q97	Spirometers											
Q98	Splints											
Q99	Sterilizers											
Q100	Stethoscopes											
Q101	Stomach Pumps											
Q102	Suction Pumps											
Q103	Suction Tubes											
Q104	Surgical Gloves											
Q105	Surgical Gowns											
Q106	Surgical Knives and Scalpels											
Q107	Surgical Masks											
Q108	Surgical Staplers											
Q109	Suture Clips											
Q110	Sutures											
Q111	Tensiometers											
Q112	Thermometers											

Q113	Tourniquets											
Q114	Tracheal Tubes											
Q115	Trocars											
Q116	Trusses											
Q117	Ultrasound Sensors											
Q118	Ultra-Violet or Infra-Red Apparatus for Medical Use											
Q119	Urethrotomes											
Q120	Vaginal Retractors/Speculums											
Q121	Venous Cannula											
Q122	Ventilator Circuits											
Q123	Ventilators											
Q124	Wire Guides											
Q125	X-Ray Apparatus Used in Medical Diagnosis											
Q126	X-Ray Control Panels/Desks											
Q127	X-Ray Generators/Producing Apparatus											
Q128	X-Ray Screens											
Comments:												

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 3.a **Critical Commodities - Non-U.S. Suppliers**

Identify any components, manufacturing materials, or finished products **provided by suppliers based outside the United States** that are critical to the final manufacture of the products identified in the previous section. Indicate the product area and product name(s) for which this component/material is required and the supplier's name and location. In addition, indicate whether the component/material is supplied by an internal company supplier/subsidiary or is supplied by an outside company. Finally, identify, to the best of your company's understanding, whether there is an alternate U.S.-based or non-U.S. based source available for each component/material.

Note: If your company does not manufacture a product in a particular product area, you may leave it blank.

Anasthetics

		Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/ Province	Internal Supplier/ Subsidiary?	Alternate Source?
A.	1.									
	2.									
	3.									
	4.									
	5.									
	6.									
	7.									
	8.									
	9.									
	10.									
	11.									
	12.									
	13.									
	14.									
	15.									

Analgesics

		Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/ Province	Internal Supplier/ Subsidiary?	Alternate Source?
B.	1.									
	2.									
	3.									
	4.									
	5.									
	6.									
	7.									
	8.									
	9.									
	10.									
	11.									
	12.									

	13.									
	14.									
	15.									

Antibacterials

		Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/ Province	Internal Supplier/ Subsidiary?	Alternate Source?
C.	1.									
	2.									
	3.									
	4.									
	5.									
	6.									
	7.									
	8.									
	9.									
	10.									
	11.									
	12.									
	13.									
	14.									
	15.									

Antibiotics

		Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/ Province	Internal Supplier/ Subsidiary?	Alternate Source?
D.	1.									
	2.									
	3.									
	4.									
	5.									
	6.									
	7.									
	8.									
	9.									
	10.									
	11.									
	12.									
	13.									
	14.									
	15.									

Comments:	

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 3.b **Critical Commodities - Non-U.S. Suppliers**

Identify any components, manufacturing materials, or finished products **provided by suppliers based outside the United States** that are critical to the final manufacture of the products identified in the previous section. Indicate the product area and product name(s) for which this component/material is required and the supplier's name and location. In addition, indicate whether the component/material is supplied by an internal company supplier/subsidiary or is supplied by an outside company. Finally, identify, to the best of your company's understanding, whether there is an alternate U.S.-based or non-U.S. based source available for each component/material.

Note: If your company does not manufacture a product in a particular product area, you may leave it blank.

Anticonvulsants, Sedatives, Relaxants

		Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/ Province	Internal Supplier/ Subsidiary?	Alternate Source?
A.	1.									
	2.									
	3.									
	4.									
	5.									
	6.									
	7.									
	8.									
	9.									
	10.									
	11.									
	12.									
	13.									
	14.									
	15.									

Anti-Inflammatories

		Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/ Province	Internal Supplier/ Subsidiary?	Alternate Source?
B.	1.									
	2.									
	3.									
	4.									
	5.									
	6.									
	7.									
	8.									
	9.									
	10.									
	11.									
	12.									

	13.									
	14.									
	15.									

Antileprosy

		Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/ Province	Internal Supplier/ Subsidiary?	Alternate Source?
C.	1.									
	2.									
	3.									
	4.									
	5.									
	6.									
	7.									
	8.									
	9.									
	10.									
	11.									
	12.									
	13.									
	14.									
	15.									

Antiprotozoals

		Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/ Province	Internal Supplier/ Subsidiary?	Alternate Source?
D.	1.									
	2.									
	3.									
	4.									
	5.									
	6.									
	7.									
	8.									
	9.									
	10.									
	11.									
	12.									
	13.									
	14.									
	15.									

Comments:	

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 3.c **Critical Commodities - Non-U.S. Suppliers**

Identify any components, manufacturing materials, or finished products **provided by suppliers based outside the United States** that are critical to the final manufacture of the products identified in the previous section. Indicate the product area and product name(s) for which this component/material is required and the supplier's name and location. In addition, indicate whether the component/material is supplied by an internal company supplier/subsidiary or is supplied by an outside company. Finally, identify, to the best of your company's understanding, whether there is an alternate U.S.-based or non-U.S. based source available for each component/material.

Note: If your company does not manufacture a product in a particular product area, you may leave it blank.

Antivirals

		Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/ Province	Internal Supplier/ Subsidiary?	Alternate Source?
A.	1.									
	2.									
	3.									
	4.									
	5.									
	6.									
	7.									
	8.									
	9.									
	10.									
	11.									
	12.									
	13.									
	14.									
	15.									

Cancer Treatments

		Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/ Province	Internal Supplier/ Subsidiary?	Alternate Source?
B.	1.									
	2.									
	3.									
	4.									
	5.									
	6.									
	7.									
	8.									
	9.									
	10.									
	11.									
	12.									

	13.									
	14.									
	15.									

Cardiovasculars

		Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/ Province	Internal Supplier/ Subsidiary?	Alternate Source?
C.	1.									
	2.									
	3.									
	4.									
	5.									
	6.									
	7.									
	8.									
	9.									
	10.									
	11.									
	12.									
	13.									
	14.									
	15.									

Hormones

		Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/ Province	Internal Supplier/ Subsidiary?	Alternate Source?
D.	1.									
	2.									
	3.									
	4.									
	5.									
	6.									
	7.									
	8.									
	9.									
	10.									
	11.									
	12.									
	13.									
	14.									
	15.									

Comments:	

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 3.d **Critical Commodities - Non-U.S. Suppliers**

Identify any components, manufacturing materials, or finished products **provided by suppliers based outside the United States** that are critical to the final manufacture of the products identified in the previous section. Indicate the product area and product name(s) for which this component/material is required and the supplier's name and location. In addition, indicate whether the component/material is supplied by an internal company supplier/subsidiary or is supplied by an outside company. Finally, identify, to the best of your company's understanding, whether there is an alternate U.S.-based or non-U.S. based source available for each component/material.

Note: If your company does not manufacture a product in a particular product area, you may leave it blank.

Immunosuppressants

		Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/ Province	Internal Supplier/ Subsidiary?	Alternate Source?
A.	1.									
	2.									
	3.									
	4.									
	5.									
	6.									
	7.									
	8.									
	9.									
	10.									
	11.									
	12.									
	13.									
	14.									
	15.									

Stimulants

		Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/ Province	Internal Supplier/ Subsidiary?	Alternate Source?
B.	1.									
	2.									
	3.									
	4.									
	5.									
	6.									
	7.									
	8.									
	9.									
	10.									
	11.									
	12.									

	13.									
	14.									
	15.									

Vaccines

		Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/ Province	Internal Supplier/ Subsidiary?	Alternate Source?
C.	1.									
	2.									
	3.									
	4.									
	5.									
	6.									
	7.									
	8.									
	9.									
	10.									
	11.									
	12.									
	13.									
	14.									
	15.									

Other Products

		Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/ Province	Internal Supplier/ Subsidiary?	Alternate Source?
D.	1.									
	2.									
	3.									
	4.									
	5.									
	6.									
	7.									
	8.									
	9.									
	10.									
	11.									
	12.									
	13.									
	14.									
	15.									

Comments:	

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 3.e **Critical Commodities - Non-U.S. Suppliers**

Identify any components, manufacturing materials, or finished products **provided by suppliers based outside the United States** that are critical to the final manufacture of the products identified in the previous section. Indicate the product area and product name(s) for which this component/material is required and the supplier's name and location. In addition, indicate whether the component/material is supplied by an internal company supplier/subsidiary or is supplied by an outside company. Finally, identify, to the best of your company's understanding, whether there is an alternate U.S.-based or non-U.S. based source available for each component/material.

Note: If your company does not manufacture a product in a particular product area, you may leave it blank.

Surgical and Medical Equipment

		Component/Manufacturing Material/Finished Product	Product Area	Product Name(s)	Supplier Name	Country	City	State/ Province	Internal Supplier/ Subsidiary?	Alternate Source?
A.	1.									
	2.									
	3.									
	4.									
	5.									
	6.									
	7.									
	8.									
	9.									
	10.									
	11.									
	12.									
	13.									
	14.									
	15.									
	16.									
	17.									
	18.									
	19.									
	20.									
	21.									
	22.									
	23.									
	24.									
	25.									
	26.									
	27.									
	28.									
	29.									
	30									

Comments:

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 4.a **Critical Commodities - Utilization**

Based on the products identified in the Section 2, indicate your company's manufacturing capacity utilization rate for each **product area** from 2007-2010. Indicate your company's maximum annual manufacturing capacity in units for 2009. In addition, using your company's 2010 production as a baseline, estimate the lead time required to increase production of each product area by the specified amount. For the purpose of this estimate, make the following assumptions:

1) Existing U.S. production facilities are to be operated at maximum practical productive capacity;
2) Labor availability reflects normal local market conditions;
3) Material availability reflects normal local market conditions; and
4) Facilities operate at the maximum rate possible given technological constraints.

Finally, from the drop-down list provided, select the primary factor that would prevent a production increase, if applicable.

Note: If your company does not manufacture a product in a particular product area, you may leave it blank.

Anaesthetics

		Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
			2007	2008	2009	2010	# of Units	Unit of Measure			
A.	1.										
	2.										
	3.										
	4.										
	5.										
	6.										
	7.										
	8.										
	9.										
	10.										

Analgesics

		Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
			2007	2008	2009	2010	# of Units	Unit of Measure			
B.	1.										
	2.										
	3.										
	4.										
	5.										
	6.										
	7.										
	8.										
	9.										
	10.										

Antibacterials

		Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
			2007	2008	2009	2010	# of Units	Unit of Measure			
C.	1.										
	2.										
	3.										
	4.										
	5.										
	6.										
	7.										
	8.										
	9.										
	10.										

Antibiotics

		Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
			2007	2008	2009	2010	# of Units	Unit of Measure			
D.	1.										
	2.										
	3.										
	4.										
	5.										
	6.										
	7.										
	8.										
	9.										
	10.										

Comments:	

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 4.b **Critical Commodities - Utilization**

Based on the products identified in the Section 2, indicate your company's manufacturing capacity utilization rate for each **product area** from 2007-2010. Indicate your company's maximum annual manufacturing capacity in units for 2009. In addition, using your company's 2010 production as a baseline, estimate the lead time required to increase production of each product area by the specified amount. For the purpose of this estimate, make the following assumptions:

1) Existing U.S. production facilities are to be operated at maximum practical productive capacity;
2) Labor availability reflects normal local market conditions;
3) Material availability reflects normal local market conditions; and
4) Facilities operate at the maximum rate possible given technological constraints.

Finally, from the drop-down list provided, select the primary factor that would prevent a production increase, if applicable.

Note: If your company does not manufacture a product in a particular product area, you may leave it blank.

Anticonvulsants, Sedatives, Relaxants

		Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
			2007	2008	2009	2010	# of Units	Unit of Measure			
A.	1.										
	2.										
	3.										
	4.										
	5.										
	6.										
	7.										
	8.										
	9.										
	10.										

Anti-Inflammatories

		Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
			2007	2008	2009	2010	# of Units	Unit of Measure			
B.	1.										
	2.										
	3.										
	4.										
	5.										
	6.										
	7.										
	8.										
	9.										
	10.										

Antileprosy

		Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
			2007	2008	2009	2010	# of Units	Unit of Measure			
C.	1.										
	2.										
	3.										
	4.										
	5.										
	6.										
	7.										
	8.										
	9.										
	10.										

Antiprotozoals

		Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
			2007	2008	2009	2010	# of Units	Unit of Measure			
D.	1.										
	2.										
	3.										
	4.										
	5.										
	6.										
	7.										
	8.										
	9.										
	10.										

Comments:	

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 4.c **Critical Commodities - Utilization**

Based on the products identified in the Section 2, indicate your company's manufacturing capacity utilization rate for each **product area** from 2007-2010. Indicate your company's maximum annual manufacturing capacity in units for 2009. In addition, using your company's 2010 production as a baseline, estimate the lead time required to increase production of each product area by the specified amount. For the purpose of this estimate, make the following assumptions:

1) Existing U.S. production facilities are to be operated at maximum practical productive capacity;
2) Labor availability reflects normal local market conditions;
3) Material availability reflects normal local market conditions; and
4) Facilities operate at the maximum rate possible given technological constraints.

Finally, from the drop-down list provided, select the primary factor that would prevent a production increase, if applicable.

Note: If your company does not manufacture a product in a particular product area, you may leave it blank.

Antivirals

		Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
			2007	2008	2009	2010	# of Units	Unit of Measure			
A.	1.										
	2.										
	3.										
	4.										
	5.										
	6.										
	7.										
	8.										
	9.										
	10.										

Cancer Treatments

		Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
			2007	2008	2009	2010	# of Units	Unit of Measure			
B.	1.										
	2.										
	3.										
	4.										
	5.										
	6.										
	7.										
	8.										
	9.										
	10.										

Cardiovasculars

		Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
			2007	2008	2009	2010	# of Units	Unit of Measure			
C.	1.										
	2.										
	3.										
	4.										
	5.										
	6.										
	7.										
	8.										
	9.										
	10.										

Hormones

		Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
			2007	2008	2009	2010	# of Units	Unit of Measure			
D.	1.										
	2.										
	3.										
	4.										
	5.										
	6.										
	7.										
	8.										
	9.										
	10.										

Comments:	

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 4.d **Critical Commodities - Utilization**

Based on the products identified in the Section 2, indicate your company's manufacturing capacity utilization rate for each **product area** from 2007-2010. Indicate your company's maximum annual manufacturing capacity in units for 2009. In addition, using your company's 2010 production as a baseline, estimate the lead time required to increase production of each product area by the specified amount. For the purpose of this estimate, make the following assumptions:

1) Existing U.S. production facilities are to be operated at maximum practical productive capacity;
2) Labor availability reflects normal local market conditions;
3) Material availability reflects normal local market conditions; and
4) Facilities operate at the maximum rate possible given technological constraints.

Finally, from the drop-down list provided, select the primary factor that would prevent a production increase, if applicable.

Note: If your company does not manufacture a product in a particular product area, you may leave it blank.

Immunosuppresants

		Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
			2007	2008	2009	2010	# of Units	Unit of Measure			
A.	1.										
	2.										
	3.										
	4.										
	5.										
	6.										
	7.										
	8.										
	9.										
	10.										

Stimulants

		Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
			2007	2008	2009	2010	# of Units	Unit of Measure			
B.	1.										
	2.										
	3.										
	4.										
	5.										
	6.										
	7.										
	8.										
	9.										
	10.										

Vaccines

		Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
			2007	2008	2009	2010	# of Units	Unit of Measure			
C.	1.										
	2.										
	3.										
	4.										
	5.										
	6.										
	7.										
	8.										
	9.										
	10.										

Other Products

		Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
			2007	2008	2009	2010	# of Units	Unit of Measure			
D.	1.										
	2.										
	3.										
	4.										
	5.										
	6.										
	7.										
	8.										
	9.										
	10.										

Comments:	

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 4.e **Critical Commodities - Utilization**

Based on the products identified in the Section 2, indicate your company's manufacturing capacity utilization rate for each **product area** from 2007-2010. Indicate your company's maximum annual manufacturing capacity in units for 2009. In addition, using your company's 2010 production as a baseline, estimate the lead time required to increase production of each product area by the specified amount. For the purpose of this estimate, make the following assumptions:

1) Existing U.S. production facilities are to be operated at maximum practical productive capacity;
2) Labor availability reflects normal local market conditions;
3) Material availability reflects normal local market conditions; and
4) Facilities operate at the maximum rate possible given technological constraints.

Finally, from the drop-down list provided, select the primary factor that would prevent a production increase, if applicable.

Note: If your company does not manufacture a product in a particular product area, you may leave it blank.

Surgical and Medical Instruments

		Product Area	Manufacturing Capacity Utilization				Maximum Production		Lead Time to Increase Production 50%	Lead Time to Double Production	Factors Preventing Production Increase
			2007	2008	2009	2010	# of Units	Unit of Measure			
A.	1.										
	2.										
	3.										
	4.										
	5.										
	6.										
	7.										
	8.										
	9.										
	10.										
	11.										
	12.										
	13.										
	14.										
	15.										
	16.										
	17.										
	18.										
	19.										
	20.										

Comments:

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 5 — Global Trade and Customer Distribution

A. If your company **imported** any health-related components, manufacturing materials, or finished products **from the list in Section 2** from 2007-2010, provide the HS-10 code used, a description of the product(s), and the total value of the imported commodities. If your company utilized more than ten HS codes, only identify the top ten by total import value.

Note: Harmonized Tariff Schedule (HTS) codes (10-digit) can be found at "HTS Online Resource Tool" located under "Research Tools" at http://www.ustic.gov/index.htm.

	HS-10 Code	Product Description(s)	2007-2010 Import Value
1.			
2.			
3.			
4.			
5.			
6.			
7.			
8.			
9.			
10.			

B. Indicate the percentage of your healthcare-related products that are sold in the United States to the following entities from 2007-2010:

	2007	2008	2009	2010
Hospitals				
Ambulatory Services				
Clinics				
Pharmacies				
Distributors/Wholesalers				
State/Local Governments				
Federal Government				
Other (specify)				
Other (specify)				
Other (specify)				
Total (Must Equal 100%)	0%	0%	0%	0%

Comments:

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 6.a		Supplier Selection Criteria		
A.	Identify the top five criteria your company considers when selecting suppliers for healthcare-related components, manufacturing materials, and finished products.	Cost		
		Domestic Source		
		Non-U.S. Source		
		Product Packages (e.g., bundles of multiple products from the same supplier)		
		Delivery Logistics/Speed		
		Sole Supplier/Unique Products		
		Substitute for a Critical Product		
		Product Quality/Manufacturing Processes		
		Product Effectiveness (e.g., fewer side effects, higher success rate)		
		Product Availability		
		Terms of Payment		
		Other (specify)		
		Other (specify)		
		Other (specify)		
B.	Does your company maintain long-term contracts with its suppliers? Explain below.			
	If 'Yes,' indicate how long, on average, these contracts last.			
Comments:				

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 6.b	Supplier Contracts		
A.	Does your company include "disruption clauses" in contracts with U.S.-based and non-U.S. based suppliers? If 'Yes,' explain the details of these clauses below (see the Definitions page for an explanation of disruption clauses).	U.S.-Based	Non-U.S. Based
B.	Does your company include "surge capacity provisions" in contracts with U.S.-based and non-U.S. based suppliers? If 'Yes,' explain the details of these clauses below (see the Definitions page for an explanation of surge capacity provisions).	U.S.-Based	Non-U.S. Based
C.	Does your company require production forecasting requirements in contracts with your suppliers? If 'Yes,' explain what these requirements entail below.		
D.	Has your company ever been a party to a rated order? A rated order is a prime contract, a subcontract, or a purchase order in support of an approved program issued in accordance with the provisions of the Defense Priorities and Allocations System (DPAS) regulation (15 CFR part 700). If 'Yes,' explain the details below.		
E.	Does your company have visibility into your suppliers' operations and inventory? If 'Yes,' identify what information your company has access to below.		
	Current production capacity		Identification of their suppliers
	Company Certifications		Location of their suppliers
	Maximum production capacity		Other (specify)
	Inventory levels		Other (specify)
	Raw material supplies		Other (specify)
	Comments:		

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 7.a	Inventory Information	
A.	Does your company maintain an inventory for healthcare-related components, manufacturing materials, and/or finished products?	
	On average, what is the normal supply level of finished, manufactured products normally kept in inventory?	
	On average, what is the normal supply level of components and manufacturing materials products normally kept in inventory?	
	If your company maintains an inventory of healthcare-related components, manufacturing materials, and/or finished products, explain how certain commodities are selected for inventory over others.	
B.	Does your company maintain a list of approved alternate supply sources for critical components, manufacturing materials, and/or finished products?	
C.	Does your company maintain relationships with multiple suppliers of the same product expressly as a contingency against supply disruptions? Explain your response.	
D.	Does your company use or manufacture any critical components, manufacturing materials, or finished products that cannot be placed in inventory for any reason? If "Yes," identify the product, its use, and the reason why it cannot be placed in inventory.	

	Product	Product's Use	Reason It Cannot Be Placed in Inventory
1.			
2.			
3.			
4.			
5.			

Comments:	

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 7.b **Supply Disruptions and Shortages**

A. Has your company had any significant supply disruptions or shortages for critical components, manufacturing materials, and/or finished products from 2007-2010?

If 'Yes,' identify the component/material/product, supplier, country, describe the issue, and detail how this product is used by your company.

	Component/Material/Product	Product Application	Supplier Name	Supplier Country	Disruption Duration (In Days)	Explanation of Supply Disruption
1.						
2.						
3.						
4.						
5.						
6.						
7.						
8.						
9.						
10.						

B. Does your company foresee a potential risk of a supply disruption or shortages for critical components, manufacturing materials, and/or finished products in the near future? Explain your response.

C. Does your company believe that it is vulnerable to serious and/or prolonged supply chain disruptions? Explain your response.

D. Is your company taking steps to reduce its vulnerability to supply chain disruptions? Explain your response.

Comments:

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 7.c		Supply Disruptions and Shortages		
A.	From 2007-2010, has your company experienced a supply disruption as a result of a transportation problem? If "Yes," describe the incident(s) below, indicating the disruption duration and the effect on your company.			
		Incident Description	Duration (in days)	Effect on Company
	1.			
	2.			
	3.			
	4.			
	5.			
B.	Are there any U.S. Government regulations or processes that hinder your company's ability to maintain a secure, continuous supply chain? If 'Yes,' identify these regulations or processes below.			
C.	Are there any non-U.S. Government regulations or processes that hinder your company's ability to maintain a secure, continuous supply chain? If 'Yes,' identify these regulations or processes below.			
	Comments:			

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 8	Cross-Sector Impacts	
A.	Are there any steps the U.S. government can take to reduce foreign dependency issues for healthcare-related products? Explain your answer.	
B.	Is your company taking any steps to reduce its exposure to foreign dependency issues? Explain your answer.	
C.	What factors does your company take into account when deciding to purchase and/or outsource overseas? Explain your answer.	
	Comments:	

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 9.a	Financial Health

Report select line items from your company's financial statement for years 2007-2010. From the drop-down indicate whether the reported income statement and balance sheet select line items are Business Unit/Division or Corporate/Whole Company financials.

Note: Business Unit/Division financials are preferred.
Note: Calendar year data is preferred.

Source of Financial Line Items:	
Reporting Schedule:	

	Income Statement (Select Line Items)	Record in $ Thousands, e.g. $12,000.00 = survey input of $12			
		2007	2008	2009	2010*
A.	Net Sales (and other revenue)				
B.	Cost of Goods Sold				
C.	Total Operating Expenses				
D.	Total Operating Income (Loss)				
E.	Total Other Income (Expenses)				
F.	Earnings Before Interest and Taxes				
G.	Interest Expense				
H.	Income Tax Expense				
I.	Net Income				

	Balance Sheet (Select Line Items)	Record in $ Thousands, e.g. $12,000.00 = survey input of $12			
		2007	2008	2009	2010*
A.	Cash				
B.	Marketable Securities				
C.	Accounts Receivable				
D.	Inventories				
E.	Total Current Assets				
F.	Property, Plant, and Equipment				
G.	Total Non-Current Assets				
H.	Total Assets				
I.	Accounts Payable				
J.	Total Current Liabilities				
K.	Long-Term Debt (less current portion)				
L.	Total Non-Current Liabilities				
M.	Total Liabilities				
N.	Total Owner's Equity				

* If data is not available for 2010, please provide estimates.

Comments:	

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 9.b		Financial Health
Use the space below to qualify with narrative any anomalies, transactions, or non-recurring events reflected in your financial statement line items, e.g. reporting restatement, merger and acquisition, chapter 11, SEC investigation, etc.		
A.	2007	
B.	2008	
C.	2009	
D.	2010	
Comments:		

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act

Section 10	Certification
The undersigned certifies that the information herein supplied in response to this questionnaire is complete and correct to the best of his/her knowledge. It is a criminal offense to willfully make a false statement or representation to any department or agency of the United States Government as to any matter within its jurisdiction (18 U.S.C.A. 1001 (1984 & SUPP. 1197))	
Company Name	
Company's Internet Address	
Name of Authorizing Official	
Title of Authorizing Official	
E-mail Address	
Phone Number and Extension	
Date Certified	
If POC is different from the above named, include below:	
Point of Contact Name	
Title of Point of Contact	
E-mail Address	
Phone Number and Extension	
Would you like a free copy of the final report?	
In the box below, please provide any additional comments or any other information you wish to include regarding this assessment.	
How many hours did it take to complete this survey?	

BUSINESS CONFIDENTIAL - Per Section 705(d) of the Defense Production Act